dihexa human studies clinical trials Dosage Protocol: Doses, Evidence & Safety First-In-Human Clinical Trial Requirement -BioPharma
Description
& Vaage, N
Higher doses of 5 mg and up are two to three times per week typically 20 days on the protocol followed by a break of 10 days
This is the pharmacological basis for CagriSema : in REDEFINE 1, the combination produced 20.4% mean weight loss versus 11.8% for cagrilintide alone and 14.9% for semaglutide alone
Generally well-tolerated BPC-157 has a favorable side-effect profile
No published research exists on this exact combination yet
